Novocure reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025.
Total preliminary net revenues for the year were $655.4 million, an 8% increase compared to the prior year.
Cash, cash equivalents, and short-term investments were $448.3 million as of December 31, 2025.
Record Annual Revenue
Novocure achieved record annual revenue in 2025, showing financial strength for future growth opportunities in 2026.
Global Oncology Company
Novocure focuses on extending survival in aggressive forms of cancer through its innovative therapy, Tumor Treating Fields (TTFields).
Operational Growth
Active patients on TTFields therapy globally reached 4,620 by December 31, 2025.
- The financial updates revealed a positive trend with a significant increase in total net revenues for the year and fourth quarter.
- Novocure's operational updates showcase steady growth in active patients on various therapies, indicating a positive trajectory for the company's impact in oncology treatment.
Novocure's performance in 2025 demonstrates its success in revenue growth and operational expansion, positioning the company for continued progress in 2026.